Vedanta Biosciences Inc.

Address: 19 Blackstone Street

Sponsor Overview

assignment

Specializations

Gastrointestinal infectious disease

Vedanta Biosciences Inc. is active in clinical research on Clostridioides difficile infection, with a focus on preventing recurrence and addressing the disruption of the intestinal microbial ecosystem associated with this condition.

Recurrent Clostridioides difficile infection
Gut microbiome restoration
Infectious diarrhoeal disease

The sponsor’s work in this area is centered on therapies designed for patients at risk of repeated infection and ongoing gastrointestinal complications.

Inflammatory bowel disease

The company also funds research in mild-to-moderate ulcerative colitis, a chronic inflammatory bowel disease marked by mucosal inflammation and impaired intestinal function.

Ulcerative colitis
Colonic inflammation
Endoscopic response

This therapeutic area reflects interest in improving disease control in patients with active colitis and persistent gastrointestinal symptoms.

Microbiome-based therapeutics

Vedanta Biosciences Inc. focuses on microbiome-based therapy approaches that target the intestinal microbial community as a way to influence disease activity in both infectious and inflammatory settings.

Live biotherapeutic products
Microbial consortia
Intestinal ecosystem modulation

Its clinical portfolio places the gastrointestinal microbiota at the center of therapeutic development.

Clinical gastroenterology

The sponsor’s trials are concentrated in gastroenterology, with research sites spread across multiple countries and a strong emphasis on conditions affecting the colon and lower gastrointestinal tract.

Colonic disease
Intestinal inflammation
Lower gastrointestinal disorders

This includes clinical evaluation in patients with recurrent infection and chronic inflammatory bowel disease.

Trial Name	Country	Status
Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of VE202 in Mild-to-Moderate Ulcerative Colitis Patients	Bulgaria Czechia Hungary Lithuania Poland The Netherlands	Not Recruiting
Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of VE303 for Recurrent Clostridioides difficile Infection Prevention in Adults	Belgium Bulgaria Czechia Denmark France Germany Hungary Ireland Italy Poland Portugal Romania Spain The Netherlands	Recruiting